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Abstract
Background:
The American College of Cardiology Foundation/American Heart Association Task Force recommends
morphine for patients with ST-elevation myocardial infarction and for patients undergoing primary
percutaneous coronary intervention (PPCI). A drug-to-drug interaction between morphine and the preferred
antiplatelets have been studied to determine the adverse effects on such a combination in antiplatelets. There
is an increase risk of thrombic events if platelets are not effectively inhibited during PPCI. The primary aim of
this systematic review is to clarify which effects exist on the efficacy of antiplatelet from co-administration of
morphine in the setting of acute coronary syndrome (ACS). The secondary aim is to determine if the dose or
type of the antiplatelet is a means to overcome the effects of morphine or whether the use of morphine use in
ACS should be questioned as it could possibly lead to treatment failure.
Methods:
An exhaustive search of the available medical literature was conducted using MEDLINE-Ovid, CINAHL, and
Web of Science. Keywords included: morphine, myocardial infarction, STEMI, acute coronary syndrome,
antiplatelet, prasugrel, ticagrelor, clopidogrel. Relevant articles were assessed using the Grading of
Recommendations, Assessment, and Evaluation (GRADE) system.
Results:
The initial search of databases resulted in 649 studies. Application of eligibility criteria and elimination of
duplicates narrowed the search down to 7 studies. With further exclusion criteria applied, 4 studies remained.
Three of the remaining studies were randomized, double-blind, placebo-controlled, cross-over trials. One final
study was a patient-level integrated analysis. The antiplatelets focused on in the studies were: clopidogrel,
ticagrelor, and prasugrel. All 4 studies showed an impact of morphine on the pharmacodynamics of each
platelet and the pharmacokinetics of some of the antiplatelets.
Conclusion:
Morphine co-administered with antiplatelets in patients with STEMI has the potential to diminish the effects
of specific P2Y12 inhibitors. Morphine diminishes pharmacodynamic effects in all recommended antiplatelets
and diminishes pharmacokinetics in certain antiplatelets as well. As emerging evidence continues to show the
negative impacts of morphine in patients with ACS, clinicians need to be judicious in their use of morphine
when co-administered with an antiplatelet.
Keywords: Morphine, antiplatelet, clopidogrel, ticagrelor, prasugrel, acute coronary syndrome, PPCI,
myocardial infarction, STEMI
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Abstract 
Background:  
The American College of Cardiology Foundation/American Heart Association Task 
Force recommends morphine for patients with ST-elevation myocardial infarction and for 
patients undergoing primary percutaneous coronary intervention (PPCI). A drug-to-drug 
interaction between morphine and the preferred antiplatelets have been studied to 
determine the adverse effects on such a combination in antiplatelets. There is an increase 
risk of thrombic events if platelets are not effectively inhibited during PPCI. The primary 
aim of this systematic review is to clarify which effects exist on the efficacy of 
antiplatelet from co-administration of morphine in the setting of acute coronary syndrome 
(ACS). The secondary aim is to determine if the dose or type of the antiplatelet is a 
means to overcome the effects of morphine or whether the use of morphine use in ACS 
should be questioned as it could possibly lead to treatment failure. 
Methods: 
An exhaustive search of the available medical literature was conducted using MEDLINE-
Ovid, CINAHL, and Web of Science. Keywords included: morphine, myocardial 
infarction, STEMI, acute coronary syndrome, antiplatelet, prasugrel, ticagrelor, 
clopidogrel. Relevant articles were assessed using the Grading of Recommendations, 
Assessment, and Evaluation (GRADE) system.  
Results:   
The initial search of databases resulted in 649 studies. Application of eligibility criteria 
and elimination of duplicates narrowed the search down to 7 studies. With further 
exclusion criteria applied, 4 studies remained. Three of the remaining studies were 
randomized, double-blind, placebo-controlled, cross-over trials. One final study was a 
patient-level integrated analysis. The antiplatelets focused on in the studies were: 
clopidogrel, ticagrelor, and prasugrel. All 4 studies showed an impact of morphine on the 
pharmacodynamics of each platelet and the pharmacokinetics of some of the antiplatelets. 
Conclusion:   
Morphine co-administered with antiplatelets in patients with STEMI has the potential to 
diminish the effects of specific P2Y12 inhibitors. Morphine diminishes pharmacodynamic 
effects in all recommended antiplatelets and diminishes pharmacokinetics in certain 
antiplatelets as well. As emerging evidence continues to show the negative impacts of 
morphine in patients with ACS, clinicians need to be judicious in their use of morphine 
when co-administered with an antiplatelet.  
Keywords: Morphine, antiplatelet, clopidogrel, ticagrelor, prasugrel, acute coronary 
syndrome, PPCI, myocardial infarction, STEMI 
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Morphine in Myocardial Infarction: Delay in Platelet 
Inhibition due to Morphine Administered to Patients 
Presenting with Acute Coronary Syndrome  
 
BACKGROUND 
 In 2009, approximately 683 000 patients were discharged from US hospitals with 
the diagnosis of ACS. About 25-40% of acute myocardial infarction presentations are 
ST-elevation myocardial infarctions (STEMI).1-3 Reperfusion therapy is recommended 
for patients with STEMI, specifically in those presenting to the ER within 12 to 24 hours 
who also have symptoms of ongoing ischemia and with associated EKG changes. For 
these patients, Primary percutanous coronary intervention (PPCI) is the preferred 
strategy.1,2, 4-6  Initial treatment for chest pain associated with an MI is intravenous 
morphine (4-8 mg initially followed by 2-8 mg every 5-15 minutes).1-2  Morphine can 
lessen anxiety, support breathing, and help ventricular loading conditions.1-2 In patients 
who meet eligibility criteria and undergo PPCI for STEMI, it is recommended to provide 
patients with a loading dose (LD) of a P2Y12 receptor inhibitor early and prior to PPCI, in 
addition to a dose of aspirin between 162 to 325 mg. The choices of P2Y12 inhibitors are: 
clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 184 mg.2  
	 It	is	gathered	only	from	expert	opinion	to	administer	morphine	for	pain	control	in	patients	with	an	MI.	The	benefit	of	morphine	in	this	population	has	not	been	proven	through	sufficient	randomized	control	trials	(RCT).7,8	In	patients	with	STEMI,	morphine	has	even	been	associated	with	higher	mortality	and	less	effective	reperfusion	after	PPCI.9-11	The ATLANTIC trial13  found that patients who did not 
receive morphine when diagnosed with STEMI, had considerable improvement in the 
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EKG readings, stating these patients also had a significant P value for interaction between 
morphine use and time of ticagrelor administration.7,12,14   
 In 2012, Parodi et al7 conducted a randomized study to investigate the onset times 
of the newer P2Y12 inhibitors (prasugrel and ticagrelor) in STEMI. In this study, it was 
hypothesized that there was an associated delayed antiplatelet effect caused by morphine 
use in the first hours of a STEMI.7,15 Morphine became an independent predictor of high 
residual platelet reactivity (HRPR) (OR: 5.29; 95% CI: 1.44 to 19.49; p=0.012).15 Shortly 
following, Hobl et al8 looked at the interaction of Morphine with Clopidogrel, finding 
that morphine does indeed decrease plasma concentrations and effects of Clopidogrel. 
After these studies, there have been very few trials performed to assess the true drug-to-
drug interaction of morphine and antiplatelets in trying to determine which antiplatelet, if 
any, has the least decrease in efficacy when co-administered with morphine.  
 The primary aim of this systematic review is to clarify which effects exist on 
antiplatelet efficacy from co-administration of morphine in the setting of ACS. The 
secondary aim is to determine if the dose of the antiplatelet is a means to overcome the 
effects of morphine or whether the overall use of morphine in ACS should be questioned. 
Understanding of antiplatelet effects of morphine may challenge the overall benefit of 
morphine use in patients with ACS and cause providers to think about possible other 
forms of pain control which do not pose a risk of treatment failure due to delay in platelet 
inhibition.8 
 
 
	 9	
METHODS 
 An exhaustive search of the available medical literature was performed using 
MEDLINE-Ovid, CINAHL, and Web of Science. The keywords included: morphine, 
myocardial infarction, STEMI, acute coronary syndrome, antiplatelet, prasugrel, 
ticagrelor, clopidogrel. The search was narrowed to include articles between the years 
2010 and 2016. Exclusion criteria applied to studies not in the English or Spanish 
language and trials on animals. Articles were excluded if they did not look specifically at 
the effects of morphine on antiplatelets in myocardial infarction. Bibliographies of each 
article were further searched for relevant sources. Chosen articles were assessed for 
quality using the Grading of Recommendations, Assessment, and Evaluation (GRADE).16  
 
RESULTS 
 The initial search of databases resulted in 649 studies. Application of eligibility 
criteria and elimination of duplicates narrowed the search down to 7 studies. With further 
exclusion criteria applied, 4 studies remained. Three of the remaining studies were 
randomized, double-blind, placebo-controlled, cross-over trials.8,9,17 One final study was 
a patient-level integrated analysis.7 See Table I and Figure I. The selected antiplatelets for 
study included: clopidogrel, ticagrelor, and prasugrel. The three RCTs8,9,17 each studied a 
different antiplatelet whereas the observational study7 used both prasugrel and ticagrelor 
as the chosen antiplatelets to study. Dosing of the antiplatelets was determined by Task 
Force Guidelines.1 Each was a loading dose. The dose of clopidogrel studied was 
600mg.8 The dose of prasugrel was 60 mg PO.7,17 The dose of ticagrelor was either 180 
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mg7,9 or 360 mg.7 The use of 360 mg was in the observational study7 and this was a 
decision made by the provider in the emergent situation. 
 The three randomized controlled trials8,9,17 included patient volunteers who were 
all deemed to be healthy. In the observational trial7, the patients underwent PPCI after 
diagnosis of STEMI. In each study, the patients received the recommended dose of 5 mg 
of intravenous morphine co-administered with the chosen antiplatelet.7-9,17,1 In the studies 
that used a control, the chosen placebo was 0.9% NaCl.8,9,17  
The trials examined high residual platelet reactivity (HRPR) at various times after 
morphine was co-administered with a loading dose of the selected antiplatelet. In each 
study, high residual platelet reactivity was defined as P2Y12 reactivity units (PRU) ≥ 
208.7-9,17 Each trial used the HRPR measurements to determine the pharmacodymanic 
and pharmacokinetic effects of morphine on the antiplatelet. See Table II for summary of 
findings.  
 
Parodi et al Study on Morphine Interaction with Ticagrelor or Prasugrel 
  
 This patient-level integrated analysis7 sought to examine the effects of morphine 
on platelet inhibition in patients diagnosed with a STEMI undergoing PPCI. The 
researchers investigated three hundred patients, all P2Y12 inhibitor naïve across 5 
different studies.15,18-20 Each patient received a loading dose of either prasugrel (n=95) or 
ticagrelor (n=205) and underwent PPCI. They assessed platelet reactivity in the plasma to 
determine the interaction of morphine and the antiplatelet. Patients were either treated 
with morphine or not treated with morphine based on the discretion of the health care 
provider overseeing the patient.7 
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In addition to the specific antiplatelets in question, the following antithrombotic 
agents were also given at the time of PPCI: Aspirin 300 to 500 mg LD followed by 100 
mg, bivaliriduin 0.75mg/kg bolus followed by 1.75 mg/kg/h infusion or unfractionated 
heparin 70 UI/kg bolus followed by additional boluses in order to achieve an activated 
clotting time of 250-300 seconds during PPCI.7 
Parodi et al stated there eligibility criteria including: a diagnosis of STEMI within 
12 hours of symptom onset. Exclusion criteria included: age less than 18 years, active 
bleeding or bleeding diathesis, previous ischemic attack or stroke, administration of 
ticlopidine, clopidogrel, prasugrel, ticagrelor, or glycoprotein IIb/IIIa inhibitors in the 
week prior to the event, need for chronic anticoagulant therapy, known relevant 
hematologic deviations, life expectancy less than one year, known severe renal or liver 
disease, and hemodynamic instability.7 The primary endpoint was residual platelet 
reactivity measured by VerifyNow specifically 2 hours after LD. Secondary endpoints 
were the percentage of patients with HRPR at 2 hours from administration of the LD and 
the incidence of vomit (which will not be discussed in this systematic review).7  
Parodi et al state the differences between patients at baseline included: lower body 
mass index, bivalirudin use, and higher systolic blood pressure in those treated with 
morphine. The study looked at the antiplatelet agents, ticagrelor and prasugrel. High 
residual platelet reactivity (HRPR) was assessed using VerifyNow at 1, 2, and 4 hours 
post loading dose. At the end of the study, the researchers found no significant 
differences between prasugrel and ticagrelor. The researchers state it was found that at 2 
hours after the loading dose, the P2Y12 reactivity units were 187 (153-221) and 133 (102-
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165) in patients with and without morphine, respectively. HRPR at 2 hours was found in 
53 and 29% of patients with and without Morphine (P<0.0001), respectively.7   
 The researchers state the result was that patients receiving morphine had a higher 
PRU as compared to those who did not: 182.3 PRU (95% CI, 164.2-200.3) with 
morphine and 140.3 PRU (95% CI, 128.2-152.4) without morphine (with a mean 
difference of 42.0 PRU (95% CI, 19.8-64.1), P<0.001). They explain the PRU values at 2 
hours, which was the primary endpoint, were 187.3 (153.4-221.2) and 133 (102.3-165.0) 
with and without morphine (P<0.001), respectively. Parodi et al report that even up to 4 
hours post LD, the same differences remained. The researchers found there to be two 
independent predictors of HRPR, which included: Morphine use (odds ratio, 2.91 [1.71-
4.97]; P<0.0001) and age (odds ratio, 1.03 [1.01-1.05]; P=0.010). The study reports that 
morphine remained associated with HRPR even after propensity score adjustment (c-
statistic, 0.68; 95% CI, 0.66-0.70; P=0.879 for Hosmer-Lemeshow test). Overall, the 
researchers state that morphine was associated with an increased risk of HRPR several 
hours after LD using either the 208 or 230 threshold: risk ratio = 1.55 (95% CI, 1.28-
1.87), P<0.001 and risk ratio = 1.44 (95% CI: 1.20-1.86), P<0.001. Worth noting is a 
possible dose response gradient in PRU or HRPR in patients taking either the 180 mg or 
360 mg dose of ticagrelor.7 
 The authors concluded that in patients with STEMI, morphine use is associated 
with a delay in onset of action of oral antiplatelet agents due to inefficient slowing of 
platelet reactivity. They state this effect remained consistent in patients treated with either 
prasugrel or ticagrelor. The inhibitory effect of morphine was evident up to 4 hours after 
loading doses of antiplatelets.7 This study was performed after previous studies of the less 
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potent antiplatelet, clopidogrel, was found to also have an suboptimal antiplatelet effect 
by Morphine.7,21-23  
 The authors conclude their research with supporting statements from previous 
studies and discussion points on the use of morphine. They mention a previous study24 on 
delayed absorption and gastric emptying due to morphine, which poses a biological rather 
than drug to drug interaction causing the decreased plasma levels of orally administered 
drugs.7,24 Morphine may also be given to patients who are at higher risk and more actuely 
ill. These patients may have differences in hemodynamics, adrenergic activation, and 
systemic vasoconstriction causing reduction of blood volume to the abdomen. These 
differences may result in a delay in drug adsorption and reduced platelet inhibition.7 The 
authors conclude that caution should be demonstrated with morphine use in STEMI 
patients because there is great importance of platelet inhibition for these patients when 
treated by PPCI and there is such a lack of adequate data supporting the use of 
morphine.7 See Table II for summary of findings.  
 A limitation of this study is that was an observational study rather than an RCT. 
HRPR is not a precise equivalent to measure platelet effect. Another limitation is that this 
study only studied pharmacodynamics and not pharmacokinetics of the antiplatelets.7 
 
Hobl et al Study on Morphine Interaction with Clopidogrel 
  
 This randomized, double-blind, placebo-controlled, cross-over trial8 sought to 
study the potential drug-to-drug interactions between clopidogrel and morphine. The 
researchers chose to look at clopidogrel due to its relatively slow onset of action as it is a 
pro-drug that requires metabolic activation in 2 steps by cytochrome P450 enzymes.8,25 
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The study took 24 healthy volunteers and co-administered 600 mg clopidogrel with either 
placebo or the recommended 5-mg morphine dose.8,1 The researchers looked at the 
pharmacokinetics of clopidogrel as well as its antiplatelet effects. The inclusion criteria 
of the sample size was: greater than or equal to 18 years of age, non-pregnant, and the 
ability to comprehend the full nature and purpose of the study. The exclusion criteria 
were: intake of NSAIDS or other platelet inhibitors, known coagulation disorders, renal 
or liver disease, chronic infectious diseases, clinically relevant abnormal laboratory 
values, and contraindications to clopidogrel or morphine.8  
The trial was randomized, and although the pharmacists preparing the controls 
and treatments were unblinded, the physcians administering them were blinded. Those 
who analyzed the pharmacokinetics and pharmacodynamics were also blinded. After an 
overnight fast by the patients, physicians gave them a LD of 600 mg clopidogrel. The 
VASP assay and multiple electrode aggregometry were used to measure the clopidogrel 
effects. The researchers assessed pharmacokinetics using liquid chromatography tandem 
mass spectrometry. Pharmacokinetic calculations were made using Kinetica 2000 version 
3.0.Hobl et al describe that the subjects were also genotyped for CYP2C9 and CYP2C19 
polymorphisms to allow for comparisons of the effect size of morphine with genetic 
determinants of clopidogrel pharmacokinetics. Before the crossover trial began, the trial 
allowed for a fourteen-day washout period.8 
The results showed a direct delay in clopidogrel absorption when administered 
with morphine (p=0.025) and a reduced area under the curve (AUC) levels of its active 
metabolite by 34% (p=0.001). They state that morphine delayed the maximal inhibition 
of platelet aggregation on average by 2 hours (n=24; p<0.001) and residual platelet 
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aggregation was higher 1 to 4 hours after morphine injection (n=24; p<0.005). The 
researchers state that morphine also delayed the inhibition of the platelet plug formation 
under high shear rates (n=21; p<0.004). They concluded that this delay in clopidogrel 
absorption, decrease in plasma levels of the active metabolite, and the slowing and 
diminishing of its effect can lead to potential treatment failure in susceptible patients.8 
 The researchers found that in regards to the pharmacokinetic interactions of 
morphine and clopidogrel, morphine delayed maximal plasma concentrations of 
clopidgrel (Tmax: 105 vs 83 min, P=0.025) and reduced the maximum serum 
concentration (Cmax) of the clopidogrel active metobolite (from 171 to 113 ng/ml, 
P=0.025) and the total exposure was measured by the AUC0-n by 34% (16 840 vs 11 103 
ng/ml, p=0.001).8 Hobl et al state that morphine delayed the time required to maximally 
inhibit platelet aggregation (3 vs 1.25 hours, P<0.001) which shows a significant effect in 
pharmacodymaics. Residual platelet aggregation was higher 1 to 4 hours after morphine 
injection (P<0.005)(n=24). Morphine also delayed the inhibition of platelet plug 
formation under high shear rates. The study states that clopidogrel intake prolonged the 
collagen/ADP induced closure time (CADP-CT-CT) 6 h after intake from a median of 
110 to 162 seconds (P<0.01) under placebo but when morphine was co-administered, it 
did not have the same effect (105 to 106 seconds, P=0.97) (n=23; P=0.012 between 
treatments). Researchers stated clopidogrel reduced the median platelet reactivity index 
in the VASP phosphorylation assay from a median of 81% to 41% (n=10; P=0.008) and 
trend-wise less after morphine (87% vs 59%, P= 0.004; P=0.30 between treatments).8 In 
regards to genetic polymorphisms in the patient population, researchers stated that 
	 16	
morphine caused a poor metabolizer phenotype in individuals genetically prone to 
extensively metabolized clopidogrel.8 
 The researchers closed their study with the discussion point that morphine slows 
clopidogrel absorption, decreases plasma levels of the active metabolite, and slows and 
diminishes clopidogrel effects. They stated that morphine effectively reduced the 
absorption of clopidogrel so that a 600 mg LD was equivalent to a 300 mg LD. Morphine 
delayed pharmacodynamics by about 2 hours. Hobl et al state that this potential lowering 
of the effective LD of clopidogrel may lead to adverse coronary outcomes including 
death.26 The researchers assert that due to the results of their study, it is possible that co-
administration of morphine and clopidogrel should be avoided, and one should consider 
using a more potent P2Y12-inhibitor for greater efficacy when using morphine.8 See Table 
II for summary of findings.  
 The trial discuss limitations of their study saying that VASP was only included on 
a subset of the participants as they did not begin using it as a measurement until partway 
through the study. They state the trial was not designed to measure differences between 
various types of metabolizers and the trial also did not measure the pharmacodynamics 
for 24 hours but it was evident that differences lessened after 4 hours. Another limitation, 
Hobl et al state, is that the study was performed on healthy patients instead of STEMI 
patients, whose absorption may be compromised through reduced splanchnic blood 
flow.8,27  
Hobl et al Study on Morphine Interactions with Ticagrelor 
  
 This randomized, double-blind, placebo-controlled, cross-over trial9 looked to 
study the potential drug-to-drug interactions between ticagrelor and morphine. The 
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researchers chose to look at ticegrelor because it is a more potent P2Y12 inhibitor 
compared to clopidogrel, which was studied prior.8 Ticagrelor does not need hepatic 
activation like clopidogrel does, so it has a quicker onset of effect, less variability in 
response between patients and higher efficacy.9 Due to this mechanism of action, the 
researchers suspected that the drug interaction between morphine and clopidogrel could 
be overcome with the more potent ticagrelor.9 
 The study used 24 healthy volunteers with the inclusion criteria being: greater 
than or equal to 18 years of age, non-pregnant, and the ability to comprehend the full 
nature and purpose of the study. The exclusion criteria included: intake of NSAIDS or 
other platelet inhibitors, known coagulation disorders, renal or liver disease, chronic 
infectious diseases, clinically relevant abnormal laboratory values, and contraindications 
to ticagrelor or morphine.9 
The trial was randomized, and although the pharmacists preparing the controls 
and treatments were unblinded, the physcians administering them were blinded. Those 
who analyzed the pharmacokinetics and pharmacodynamics were also blinded. After an 
overnight fast by the patients, physicians gave them a LD of 180 mg ticagrelor. The 
VASP assay and multiple electrode aggregometry were used to measure the ticagrelor 
effects. The researchers assessed pharmacokinetics using liquid chromatography tandem 
mass spectrometry. Pharmacokinetic calculations were made using Kinetica 2000 version 
3.0. Before the crossover trial began, the trial allowed for a fourteen-day washout period.9 
In summary, the 24 healthy volunteers were co-administered 180 mg ticagrelor 
with either placebo or the recommended 5 mg of morphine.1,9 The researchers looked at 
the pharmacokinetics of ticagrelor and its antiplatelet effects. The results state a delay in 
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ticagrelor absorption when administered with morphine (P<0.05) by 1 hour and a reduced 
level of its active metabolite by 25-31% (P≤0.03). Hobl et al state that morphine reduced 
the drug exposure (AUC) by 22-23% (P≤0.01). The researchers found and explain that 
the pharmacodynamics of ticagrelor on platelet aggregation in whole blood, platelet plug 
formation, and VASP phosphorylation are not affected by morphine. They concluded that 
morphine decreases the pharmacokinetic effects of ticagrelor but does not inhibit its 
pharmacodynamic effects.9  
 The researchers explain that in regards to the pharmacokinetic interactions of 
morphine and ticagrelor, there was a delay in maximum plasma concentrations of 
ticagrelor (Tmax:180 vs 120 mins, P=0.016) and the active metabolite (240 vs 180 min, 
P=0.023). Hobl et al state that morphine reduced both the Cmax of ticagrelor (from 1222 to 
913 ng/mL, p=0.015) and reduced the active metabolite (from 325 to 242 ng/mL, 
P=0.028) and the total exposure as measured by AUC0-n by 22% and 23% for ticagrelor 
and it’s active metabolite (ticagrelor: 228 110 vs 177 617 ng*h/mL, p=0.011, ticagrelor 
active metabolite: 67 200 vs 52 882 ng*h/mL, p=0.009). They say that morphine did not 
influence pharmacodynamics of ticagrelor, neither whole blood aggregation nor platelet 
plug formation under high shear rates. Ticagrelor prolonged collagen/ADP induced 
closure times (CADP-CT) 6 hours after intake from a median of 96 to 167 seconds under 
placebo and from 94 to 165 seconds when morphine was co-administered (for both 
periods: P<0.001).9 
 The researchers closed their study with the discussion point that ticagrelor has the 
potential to overcome the pharmacodynamic problems of the clopidogrel-morphine 
interaction. Morphine slows gastric emptying9,24 and morphine did indeed delay drug 
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absorption, leading to a lower concentration of ticagrelor and its active metabolite by 20-
30%. However, the US Food and Drug Administration classifies a drug-to-drug 
interaction as a difference of less than or equal to 25% in AUC.9,28 Hobl et al state the 
maximal inhibition of platelets after 60-75 minutes in both treatment periods with and 
without morphine shows a lack of morphine on ticagrelor pharmacodynamics.9 
 Researchers state that providers can be confident that a LD of 180 mg ticagrelor is 
potent enough to at least partially overcome the previously observed drug-to-drug 
interaction of clopidogrel and morphine, so ticagrelor can potentially be an effective 
alternative to clopidogrel when morphine is being co-administered.9 However, the study 
reassures previous studies7,9,15 noting that reduced blood flow in sick and 
hemodynamically unstable patients may compromise drug absorption or decrease peak 
levels of active metabolite. Morphine has an effect on drug absorption already may be 
more potent on these individuals along with the utilized antiplatelets. Overall, Hobl et al 
affirm that morphine moderately decreases ticagrelor plasma concentrations but does not 
inhibit its antiplatelet effects in healthy volunteers.9 See Table II for summary of findings.  
 The researchers point out several lmitations of this study: one limitation is the 
timing of the morphine administration, which was given at a predefined point, which is 
not equivalent to an emergency situation. The dosing of the ticagrelor was administered 
with exactly 250 mL of tap water, which differs from an emergent situation. They state 
their trial was not designed to observe the pharmacodynamics for 24 hours and that it 
cannot rule out other possible drug-drug interactions that would likely happen in the 
emergency room with various patients. In this study they only looked at patients on 
morphine and ticagrelor without influence of any other drug. Another limitation is that 
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the study was performed on healthy patients rather than STEMI patients, whose 
absorption may be compromised through reduced splanchnic blood flow.9 
 
Hobl et al Study on Morphine Interactions with Prasugrel 
  
 This randomized, double-blind, placebo-controlled, cross-over trial17 looked to 
study the potential drug-to-drug interactions between prasugrel and morphine. The 
researchers state they chose to look at prasugrel because it is a more potent P2Y12 
inhibitor in comparison with clopidogrel which was studied prior this study.8 Where 
clopidogrel is converted into its active metabolite in two steps, they state prasugrel is 
hydrolyzed by esterase to an immediate metabolite and requires only one further CYP-
dependent oxidation step to generate its active compound.17 Thus, they explain, prasugrel 
poses less variability in response between patients and higher efficacy. The researchers 
suspected that the drug interaction between morphine and prasugrel would be minor as 
that compared to clopidogrel.17 
 The study used 12 healthy volunteers with the inclusion criteria being: greater 
than or equal to 18 years of age, non-pregnant, and the ability to comprehend the full 
nature and purpose of the study. The exclusion criteria were: intake of NSAIDS or other 
platelet inhibitors, known coagulation disorders, renal or liver disease, chronic infectious 
diseases, clinically relevant abnormal laboratory values, and contraindications to 
prasugrel or morphine.17 
The trial was randomized, and although the pharmacists preparing the controls 
and treatments were unblinded, the physcians administering them were blinded. Those 
who analyzed the pharmacokinetics and pharmacodynamics were also blinded. After an 
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overnight fast by the patients, physicians gave them a LD of 60 mg prasugrel. The VASP 
assay and multiple electrode aggregometry were used to measure the prasugrel effects. 
The researchers assessed pharmacokinetics using liquid chromatography tandem mass 
spectrometry. Pharmacokinetic calculations were made using Kinetica 2000 version 3.0. 
Before the crossover trial began, the trial allowed for a fourteen-day washout period.17 
In summary, 12 healthy volunteers were co-administered 60 mg prasugrel with 
either placebo or the recommended 5-mg morphine.1,9 The researchers looked at the 
pharmacokinetics of prasugrel as well as its antiplatelet effects. The researchers state the 
results show that morphine neither diminished total drug exposure (AUC), which was the 
primary endpoint, nor significantly delayed drug absorption of prasugrel. However, they 
explain, morphine did reduce maximal plasma concentrations (Cmax) of prasugrel 
metabolite by 31% (P=0.019). Hobl et al state morphine slightly delayed the onset of 
maximal inhibition of platelet plug formation under high shear rates (30 vs 20 minutes), 
but this was found to not be significant. Whole blood aggregation was not influenced in 
this study. The researchers concluded that morphine significantly decreases the maximal 
plasma concentrations of prasugrel and its active metabolite, but they make clear it does 
not diminish the effects of prasugrel on platelets to a clinically relevant degree in healthy 
volunteers. Overall, Hobl et al state that the decrease in Cmax of prasugrel and its active 
metabolite caused by morphine co-administration should gain relevance in STEMI 
patients.17  
 The researchers stated that in regards to the pharmacokinetic interactions of 
morphine and prasugrel, morphine did not significantly reduce total exposure as 
measured by AUC0-n (69 573 vs 65 991 ng x h/mL, P=0.239), which was the primary 
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endpoint. The time of maximal plasma concentrations of prasugrel active metabolite (30 
vs 38 min, P=0.798) was not influenced by morphine. Hobl et al state that morphine 
however, did reduce the Cmax of prasugrel and its active metabolite by 31% from 1388 to 
951 ng/mL (P=0.019). Whole blood aggregation of prasugrel was not influenced by the 
morphine however, it caused a slight insignificant delay in the maximal inhibition of the 
platelet plug formation under high shear rates. Hobl et al state that overall, morphine did 
not reduce the total drug exposure as measured by the AUC0-n, which was the primary 
endpoint. Morphine also did not slow the Tmax of prasugrel active metabolite. The 
researchers state that morphine did reduce the maximal plasma concentration of prasugrel 
active metabolite by 31%, which would prove significant if morphine had effects on the 
pharmacodynamics of prasugrel.17  
 The researchers closed their study with the discussion point that the 60 mg LD of 
prasugrel appears to be adequate to inhibit platelet function in healthy volunteers. They 
state that morphine co-administration moderately decreases the maximal plasma 
concentration of prasugrel and its active metabolite, but it does not inhibit its effects on 
platelets to a clinically relevant degree in healthy volunteers. See Table II for summary of 
findings.  
 The researchers discuss limitations of their study. One limitation is that the study 
was performed on healthy patients rather than STEMI patients, whose absorption may be 
compromised through reduced splanchnic blood flow.17,27 Another limitation of the study 
is the very small sample size. Twelve patients total may not be enough to draw strict 
conclusions in the generalized population.  
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DISCUSSION 
 The purpose of this systematic review of the literature was to explore the effects 
of morphine in the various recommended antiplatelets in ACS. The studies7-9,17 used in 
this review examined morphine, the recommended treatment for pain in patients 
presenting with ACS, and explored its effects on the pharmacodynamics and 
pharmacokinetics on the three most highly used antiplatelets in the setting if ACS, 
hypothesizing that morphine potentially inhibits antiplatelet efficacy. While morphine is 
the most widely recommended analgesic for treatment of chest pain in ACS, there has not 
been extensive research using randomized controlled trials on morphine or its effects on 
the other medicines used in treatment of ACS.7-9,17 Morphine has even been associated 
with poor outcomes when used in patients for treatment of ACS.7-10,17 If morphine is 
associated with less efficacious antiplatelet function in the setting of MI, perhaps 
clinicians need to look to other options for pain control in this patient population.  
In the Hobl et al study on morphine and clopidogrel,8 it was found that morphine 
delayed clopidogrel absorption, decreased plasma levels of the active metabolite of 
clopidogrel, and slowed and lowered its effects in healthy volunteers. The Hobl et al 
study on morphine effects on prasugrel17 found that morphine decreased the maximal 
plasma concentrations of prasugrel, but did not diminish its effects in healthy volunteers. 
The Hobl et al study on morphine effects on ticagrelor9 found that morphine moderately 
decreased plasma concentrations but did not inhibit its pharmacodynamics in healthy 
volunteers. The Parodi et. al study7 found that morphine is associated with a delayed 
onset of action of both ticagrelor and prasugrel. Parodi et al stated that morphine 
maintained relatively higher P2Y12 reactivity units and was associated with HRPR up to 4 
	 24	
hours after administration. Clopidogrel appears known now to have adverse effects when 
co-administered with morphine and its use is in question when ACS patients are being 
treated with morphine.8,25 It appears that with the more potent ticagrelor and 
prasugrel,7,9,15,17,22,23,25 the pharmacodynamics of these drugs may be able to overcome 
morphine’s effects. The pharmacokinetics of these two antiplatelets however, continue to 
be affected by morphine.7,9,17  
 In looking at each study considered for the purposed of this systematic review, 
variability across the studies must be considered. The Hobl et. al studies8,9,17 were RCTs 
and performed in a very controlled environment with precise timing and administration of 
each drug in question. In the Parodi et al study,7 the researchers took patients across 
several emergency, real life events, thus the timing of the administration of morphine and 
antiplatelets was not as precisely measured as the Hobl et. al studies. Additionally, In the 
Parodi et. al study,7 the administration of antiplatelets along with morphine was still 
within the realm of recommendations for the emergency room patient population,1,7,29 but 
there likely was more variability in the timing of when the patients received the morphine 
and antiplatelets. In the Hobl et al studies,8,9,17 the patients received a placebo of 0.9% 
NaCl whereas in the Parodi et al study,7 instead of receiving a placebo, these patients did 
not receive morphine at all. Overall and regardless of the variability, similar 
pharmacodynamic and pharmacokinetic effects were seen.7-9,17  
 There were strong limitations in all three of the Hobl et al studies.8,9,17 These 
studies each used a small sample size – between 12 and 24 patients. In addition to the 
small sample size, the Hobl et al studies8,9,17 only used healthy volunteers to study the 
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effects of morphine in various antiplatelets. This can confuse results in that those in a 
real-life scenario being treated with morphine and antiplatelets are not necessarily 
considered healthy. Each Hobl et al study8,9,17 addresses this large limitation. The 
important factor with this issue is that patients in an emergent setting can have varying 
degrees of hemodynamic stability, which can significantly affect the absorption and 
interactions of drugs.17,27  
 Early reperfusion is the goal in STEMI1,7,29 and if a drug-to-drug interaction 
decreases the chances or speed of this occurring, this becomes a critical issue for patients. 
If the antiplatelet effects are diminished in patients with STEMI, treatment failure can be 
the end result.8 Parodi et al7 hypothesized that patients treated with morphine in these 
situations are at higher risk. Even though Hobl et al9,17 found that prasugrel and ticagrelor 
in healthy patients do not have diminished pharmacokinetic effects when co-administered 
with morphine, Parodi et al7 states it cannot be ruled out that patients who are acutely sick 
have hemodynamic disarrangement, adrenergic activation, and systemic vasoconstriction 
all compounding the effects that morphine already has.7 Thus, it may be important and 
prudent for clinicians to think either about the dose of and specific antiplatelet they are 
using in patients with STEMI, but they must also think about the possibility of using 
alternate pain control methods.14  
 Future research in pain control in ACS will be very helpful. There is existing 
research on the hemodynamics of ill patients,7-9,17,27,29 but research on specific analgesics 
and their effects on antiplatelets may provide some alternative ways to treat chest pain 
without a decrease in effect of these drugs. Hobl et al8,9,17 postulated an RCT to clarify 
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the benefit-risk ratio of morphine in the setting of MI with severe chest pain. With early 
reperfusion as the main goal of STEMI,1,7-9,17,30 a look into reperfusion techniques will 
provide help in treating patients more efficiently as myocardial ischemic relief is the best 
chest pain control strategy.7 Kubica et al31,32 is currently performing an ongoing RCT 
called the IMPRESSION trial. This trial is looking particularly at ticagrelor co-
administration with morphine in patients presenting with myocardial infarction which 
will provide more insight into the drug to drug interactions of morphine and ticagrelor on 
acutely ill patients that the Hobl et al study9 lacks. 
CONCLUSION 
 Morphine administered for pain to patients presenting with ACS is associated 
with pharmacodynamic and pharmacokinetic effects of the antiplatelets clopidogrel, 
prasugrel, and ticagrelor. Morphine is shown to have significant drug-to-drug interactions 
with antiplatelets used in ACS but the effects appear different depending on the specific 
antiplatelet. The effects of morphine on Clopidogrel are the most profound, raising the 
question of whether Clopidogrel should even be used in STEMI patients. In conclusion, 
morphine decreases plasma concentrations of antiplatelets in both healthy patients and 
those in ACS. As emerging evidence continues to circulate on the drug-drug effects of 
morphine and antiplatelets, clinicians will do well to be aware of these effects as they 
choose specific agents for their patients in trying to provide the least harm and the most 
efficient reperfusion of ischemic vessels in myocardial infarction.  
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